How to read weight-loss peptide evidence
Mechanism diagrams do not rank clinical effectiveness or establish that broader receptor activity is automatically better. The 2023 Retatrutide trial was a phase 2 investigation; its findings must be interpreted within that study’s population and protocol. Jastreboff et al., 2023.
Lilly reported additional phase 3 Retatrutide results in July 2026 while describing it as investigational. That sponsor announcement is distinct from regulatory approval. [5]
Each product page shows the batch number and the Kovera Labs reports for that batch. This research catalogue does not provide personal weight-loss treatment. The TGA explains why research labels do not remove applicable obligations. [6][7]
Read the Retatrutide study explanation and batch-document checklist for separate scientific and analytical questions.
References and bibliography
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators. 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 389(6):514-526. doi:10.1056/nejmoa2301972.
- Eli Lilly and Company. 2026. Retatrutide results from TRIUMPH-2 and TRIUMPH-3: sponsor announcement, 23 July 2026. Accessed 27 September 2026.
- Eternal Peptides Wholesale. Peptide testing standards and report directory. Accessed 27 September 2026.
- Therapeutic Goods Administration. 2026. How we regulate therapeutic peptide products. Accessed 27 September 2026.
GLP-1 Class Research Compounds
The GLP-1 receptor agonist class has become one of the most extensively researched areas in metabolic science. GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone that acts via receptors expressed in the pancreatic beta cells, hypothalamus, brainstem, and gastrointestinal tract. Agonism of GLP-1R has been studied across glucose homeostasis, insulin secretion, gastric motility, central appetite regulation, and adipose tissue metabolism.
Retatrutide is studied for agonist activity at GIP, GLP-1 and glucagon receptors. Receptor activity and clinical outcomes are different questions; a broader receptor profile alone does not establish greater effectiveness. See the cited research overview.
Available Products & Pricing
Supplied as lyophilised powder in boxes of 10 research-grade vials. Free shipping on all orders.
Retatrutide product specifications
The remaining product information below describes Retatrutide presentations. Nominal vial amount and box quantity are product specifications, not clinical outcomes or treatment advice.
| Compound | Receptor Targets | SKU | Price |
|---|---|---|---|
| Retatrutide | GLP-1R + GIPR + GcgR | RT10 (10mg) / RT20 (20mg) | $544.50 / $891.00 |
Why Researchers Choose Eternal Peptides Wholesale
Published Batch Reports
Each product page publishes the Kovera Labs reports for its batch. Each report lists the method, stated criterion and result for its batch.
Online Research Supplier
Eternal Peptides Wholesale is an online Australian business. Dispatch origin can vary, including offshore fulfilment. Contact us about supplier and invoicing documentation before ordering.
Wholesale Box Pricing
Supplied in boxes of 10 vials at wholesale pricing. No per-vial retail markups. Structured for research procurement budgets.
Free Shipping
Free shipping on all orders. Consult our Shipping Policy for processing and delivery estimates. Dispatch origin can vary, including offshore fulfilment; Australian business ownership does not guarantee domestic stock or customs-free delivery. Kovera Labs reports for each tested batch are published on the product pages.
Frequently Asked Questions
What peptides are used in weight loss research in Australia? +
This guide covers metabolic research and the limits of applying clinical-trial results to laboratory catalogue products. See the Retatrutide research overview for its receptor profile and cited studies. For laboratory research use only.
Where can I buy GLP-1 peptides wholesale in Australia? +
Eternal Peptides Wholesale lists Retatrutide in 10mg and 20mg formats for qualified laboratory research. Each product page lists the batch, its Kovera Labs reports and the applicable terms.
How are these compounds quality verified? +
Each product page publishes the Kovera Labs reports for its batch. Each report lists the method, stated criterion and result for its batch.
Are these peptides legal to purchase in Australia for research? +
GLP-1 class compounds are supplied by Eternal Peptides Wholesale for qualified laboratory research use only — not for human therapeutic use or compounding for human administration. GLP-1 class compounds have been subject to increased TGA regulatory attention following the October 2024 compounding changes. Customers are responsible for understanding all applicable Australian regulatory requirements for their research context. For research use only.
Related Resources
Testing references updated 1 November 2026 for the published Kovera Labs report set. Original research and catalogue snapshot dates remain as stated.